FDA Approves New Drug Trikafta for Most Common Form of Cystic Fibrosis

TUESDAY, Oct. 22, 2019 — A new drug to treat most cystic fibrosis patients has been approved by the U.S. Food and Drug Administration.
Trikafta (elexacaftor/ivacaftor/tezacaftor) is the first triple combination therapy available to treat patients…
Source: Topamax